Precigen Business and Clinical Update Apr 04, 2023 at 8:30 AM EDT Precigen hosted a conference call to provide business and clinical updates for recent announcements. Webcast Supporting Materials Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T® Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors